Calithera Biosciences, Inc. (CALA)
Stock Price:
$4.24 USD
-0.03 (-0.59%)
Updated Aug 14, 2020 9:59 AM EDT - Market open
Key Info
| Market Cap |
298.82M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-86.86M |
| Shares Out |
70.56M |
| EPS (ttm) |
-1.43 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$4.24 |
| Previous Close |
$4.26 |
| Change ($) |
-0.03 |
| Change (%) |
-0.59% |
| Day's Open |
4.29 |
| Day's Range |
4.21 - 4.29 |
| Day's Volume |
27,962 |
| 52-Week Range |
2.45 - 8.18 |
More Stats
| Market Cap |
298.82M |
| Enterprise Value |
150.04M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
70.56M |
| Float |
62.81M |
| EPS (basic) |
-1.43 |
| EPS (diluted) |
-1.43 |
| FCF / Share |
-1.20 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.80M |
| Short Ratio |
6.21 |
| Short % of Float |
7.82% |
| Beta |
2.10 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.02 |
| Revenue |
n/a |
| Operating Income |
-89.40M |
| Net Income |
-86.86M |
| Free Cash Flow |
-83.10M |
| Net Cash |
148.78M |
| Net Cash / Share |
2.11 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-33.73% |
| ROE |
-61.46% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
6 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$11.10*
(162.10% upside)
Low
7.00
Current: $4.24
High
20.00
Target: 11.10
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | - | 22.25 | 25.96 | - | - | - | - | - |
| Revenue Growth | - | -14.26% | - | - | - | - | - | - |
| Gross Profit | - | 22.25 | 25.96 | - | - | - | - | - |
| Operating Income | -92.90 | -57.28 | -29.69 | -38.33 | -32.82 | -21.72 | -12.38 | -7.98 |
| Net Income | -89.86 | -54.63 | -27.83 | -38.00 | -32.64 | -21.71 | -12.38 | -7.98 |
| Shares Outstanding | 47.31 | 36.60 | 32.95 | 19.49 | 18.05 | 4.65 | 0.09 | 0.01 |
| Earnings Per Share | -1.90 | -1.49 | -0.84 | -1.95 | -1.81 | -4.67 | -131.53 | -366.13 |
| Operating Cash Flow | -78.75 | -64.84 | 13.75 | -31.03 | -29.93 | -19.23 | -11.84 | -6.99 |
| Capital Expenditures | -0.01 | -0.21 | -1.23 | -0.40 | -0.44 | -0.56 | -0.16 | -0.05 |
| Free Cash Flow | -78.75 | -65.06 | 12.52 | -31.43 | -30.37 | -19.79 | -12.00 | -7.04 |
| Cash & Equivalents | 158 | 137 | 164 | 51.83 | 69.97 | 102 | 33.94 | 2.31 |
| Total Debt | 6.72 | - | - | - | - | - | - | - |
| Net Cash / Debt | 151 | 137 | 164 | 51.83 | 69.97 | 102 | 33.94 | 2.31 |
| Assets | 169 | 143 | 192 | 54.80 | 75.75 | 105 | 34.84 | 3.06 |
| Liabilities | 26.34 | 16.01 | 42.15 | 4.89 | 3.96 | 4.40 | 1.38 | 0.91 |
| Book Value | 142 | 127 | 150 | 49.91 | 71.79 | 100 | -20.81 | -8.57 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Calithera Biosciences, Inc. |
| Country |
United States |
| Employees |
90 |
| CEO |
Susan M. Molineaux |
Stock Information
| Ticker Symbol |
CALA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CALA |
| IPO Date |
October 2, 2014 |
Description
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor for the treatment of cystic fibrosis; and CB-708, an orally administered small molecule inhibitor of CD73. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.